Location · Chino, CA
Clinical trials in Chino, CA
19 recruiting studies have a site in Chino, and 0 of them accept healthy volunteers.
19 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 3
A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Location
- Chino, CA + 12 other US sites
- Eligibility basics
- Ages 5–17
- RecruitingPhase 2
ALTO-100 in Bipolar Disorder With Depression (BD-D)
Alto Neuroscience
- Location
- Chino, CA + 38 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 3
Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol
Axsome Therapeutics, Inc.
- Location
- Chino, CA + 35 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2
Dexmedetomidine Transdermal Systems (DMTS) Treatment for Agitation Associated With Dementia of the Alzheimer's Type
Teikoku Pharma USA, Inc.
- Location
- Chino, CA + 7 other US sites
- Eligibility basics
- Any age listed
- RecruitingPhase 2
A Study to Evaluate Safety and Efficacy of ALKS 7290 Compared With Placebo in Adult Participants With Attention Deficit Hyperactivity Disorder (ALKS 7290-201)
Alkermes, Inc.
- Location
- Chino, CA + 17 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
Celgene
- Location
- Chino, CA + 31 other US sites
- Eligibility basics
- Ages 55–90
- RecruitingPhase 2
A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
Seaport Therapeutics
- Location
- Chino, CA + 26 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
Bristol-Myers Squibb
- Location
- Chino, CA + 12 other US sites
- Eligibility basics
- Ages 13–17
- RecruitingPhase 2
ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
ACADIA Pharmaceuticals Inc.
- Location
- Chino, CA + 23 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
Neurocrine Biosciences
- Location
- Chino, CA + 44 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2
A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)
Tonix Pharmaceuticals, Inc.
- Location
- Chino, CA + 25 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Location
- Chino, CA + 43 other US sites
- Eligibility basics
- Ages 55–90
- RecruitingPhase 4
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
Neurocrine Biosciences
- Location
- Chino, CA + 18 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)
Bristol-Myers Squibb
- Location
- Chino, CA + 39 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Neurocrine Biosciences
- Location
- Chino, CA + 9 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.
AbbVie
- Location
- Chino, CA + 30 other US sites
- Eligibility basics
- Ages 10–17
- RecruitingPhase 3
A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)
Bristol-Myers Squibb
- Location
- Chino, CA + 2 other US sites
- Eligibility basics
- Ages 55–90
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine
Bristol-Myers Squibb
- Location
- Chino, CA + 19 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2
Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive Dyskinesia
Neurocrine Biosciences
- Location
- Chino, CA + 17 other US sites
- Eligibility basics
- Ages 18–75